Overview

Taima TB: 3HP Study

Status:
Completed

Trial end date:
2019-08-15

Target enrollment:

Participant gender:

Summary

This phase IV clinical study trial will be conducted among persons who require treatment for LTBI treatment in Iqaluit, Nunavut and Ottawa, Ontario. The primary objective of this study is to compare the proportion of people who complete directly observed prophylactic treatment (DOPT) using the new 3HP regimen to the current standard of 9 months INH.

Phase:

Phase 4

Details

Lead Sponsor:

Ottawa Hospital Research Institute

Collaborators:

Government of Canada
Government of Nunavut

Treatments:

Rifapentine